Androgen Receptor Variants in Bone Metastases
Author Information
Author(s): Hörnberg Emma, Ylitalo Erik Bovinder, Crnalic Sead, Antti Henrik, Stattin Pär, Widmark Anders, Bergh Anders, Wikström Pernilla
Primary Institution: Umeå University, Sweden
Hypothesis
The expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Conclusion
Higher levels of androgen receptor variants in castration-resistant prostate cancer bone metastases are linked to a poor prognosis.
Supporting Evidence
- AR-Vs were detected in most primary tumors and metastases.
- AR-V567es was found in 23% of CRPC bone metastases.
- High levels of AR-Vs were associated with short survival.
- Patients with AR-V high had a median survival of only 2 months.
Takeaway
This study found that certain changes in prostate cancer cells can make them resistant to treatment and lead to shorter survival times.
Methodology
The study analyzed bone metastases from patients using RT-PCR and gene expression profiling.
Limitations
The study is based on a limited number of patients and results need verification in further studies.
Participant Demographics
Median age of participants was 60 years, with a range of 48-68 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website